The reported growth gains momentum when accounting for one-time inventory adjustments. During the second quarter of 2025, BioArctic’s figures were bolstered by a 5.3 billion yen stockpiling effect in the Chinese market. When excluding that specific impact, underlying royalty revenues for the current quarter demonstrate a robust 43 percent year-over-year increase.

BioArctic, which discovered the monoclonal antibody, maintains a long-term development and commercialization partnership with Eisai. While Eisai manages global regulatory and commercial activities, BioArctic retains rights to market the drug in the Nordic region. The company is scheduled to release its full financial report for the second quarter on August 26, 2026.